Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.6%

3 terminated/withdrawn out of 22 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

14%

3 trials in Phase 3/4

Results Transparency

0%

0 of 13 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A
12(80.0%)
Phase 4
2(13.3%)
Phase 3
1(6.7%)
15Total
N/A(12)
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT07314229Not ApplicableRecruiting

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Role: collaborator

NCT02194881Completed

Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation

Role: collaborator

NCT03424486Completed

Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis

Role: collaborator

NCT03492567Not ApplicableCompleted

Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.

Role: collaborator

NCT02342964Not ApplicableCompleted

Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis

Role: collaborator

NCT03052556Not ApplicableCompleted

Human Papillomavirus and Cervical Dysplasia in Women With Cystic Fibrosis

Role: collaborator

NCT06356246Recruiting

Oral Health Status of Cystic Fibrosis Patients. An Online Survey in Collaboration With the Vaincre la Mucoviscidose Patient Association.

Role: collaborator

NCT02965326Not ApplicableRecruiting

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

Role: collaborator

NCT02869932Not ApplicableCompleted

Prospective Study of the Phenotypic Expression of Cystic Fibrosis (CF) Screened Positive Newborns With an Atypical Form of CF (DPAM)

Role: collaborator

NCT05654480Unknown

Combating Diagnostic Wandering and Impasse for Cystic Fibrosis

Role: collaborator

NCT03587493Not ApplicableUnknown

T-lymphocytes CD8+/HLA-DR+ and Acute Rejection After Lung Transplantation

Role: collaborator

NCT04879381Completed

Epidemiology of Anaerobic Bacteria in Cystic Fibrosis Patients: Descriptive and Non-interventional Study

Role: collaborator

NCT02894619Completed

Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)

Role: collaborator

NCT03670472Recruiting

Correction of Nonsense Mutations in Cystic Fibrosis

Role: collaborator

NCT02342951Not ApplicableCompleted

Evaluation of the Lung Clearance Index

Role: collaborator

NCT01837589Not ApplicableCompleted

Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis

Role: collaborator

NCT02884622Not ApplicableCompleted

DNA Methylation and Lung Disease in Cystic Fibrosis

Role: collaborator

NCT01586728Not ApplicableTerminated

Oxygen Therapy in Cystic Fibrosis

Role: collaborator

NCT01293019Phase 3Completed

Osteopathic Treatment in Adult Patients With Cystic Fibrosis

Role: collaborator

NCT00244270Phase 4Completed

Cystic Fibrosis and Totally Implantable Vascular Access Devices

Role: collaborator